^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1)

    i
    Other names: KIR3DL1, Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1, NKB1, CD158E1, NKB1B, Killer Cell Immunoglobulin-Like Receptor, Three Domains, Long Cytoplasmic Tail, 1, P70 Natural Killer Cell Receptor Clones CL-2/CL-11, Killer Cell Immunoglobulin-Like Receptor 3DL1, HLA-BW4-Specific Inhibitory NK Cell Receptor, Natural Killer-Associated Transcript 3, CD158 Antigen-Like Family Member E, P70 NK Receptor CL-2/CL-11, CD158e1/2, CD158e2, NKAT-3, Cl-11, Nkat3, AMB11, NKAT3, Cl-2, KIR, P70 Killer Cell Inhibitory Receptor, MHC Class I NK Cell Receptor, KIR Antigen 3DL1, CD158e Antigen, KIR3DL1/S1, KIR2DL5B, CD158E
    4d
    KIR AA individuals possess strong inhibitory KIR alleles alongside HLA ligands that are protective against leukemia in the Chinese population. (PubMed, Front Genet)
    These data suggest that KIR AA individuals possess strong inhibitory interactions of KIR alleles and HLA, arming KIR AA + NK cells to meditate stronger alloreactivity and cytotoxicity against leukemia cells with lowered HLA expression. Our findings may provide valuable insights into leukemia pathogenesis and better understanding of the immune mechanisms.
    Journal
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • HLA-B (Major Histocompatibility Complex, Class I, B) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3) • KIR2DS4 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 4) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    2ms
    HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer. (PubMed, Oncoimmunology)
    Mechanisms by which KIR3DL1/Bw4 interaction interferes with BCG-induced NK cell proliferation and the production of cytokines and icNO, warrant further investigation. HLA-I genotyping should be investigated as a useful biomarker to personalize BCG immunotherapy in BC.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • HLA-B (Major Histocompatibility Complex, Class I, B) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • IL1B (Interleukin 1, beta) • NKG2D (killer cell lectin like receptor K1) • CD226 (CD226 Molecule)
    6ms
    Clinicopathological features and prognosis of aggressive natural killer-cell leukemia: an analysis of 27 cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    Tumor cells exhibit significant morphological variation, and bone marrow infiltration patterns are diverse. Accurate recognition, early diagnosis, and timely chemotherapy are critical to improving the prognosis of patients with ANKL.
    Retrospective data • Journal • IO biomarker
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • GZMB (Granzyme B) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • CD2 (CD2 Molecule) • KIR2DS4 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 4) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    8ms
    Integrating killer cell immunoglobulin-like receptor high-resolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation. (PubMed, Haematologica)
    Highly inhibiting KIR3DL1 - HLA-B and HLA-A (Bw4) interactions were associated with a reduced relapse incidence as compared to weak and non-inhibiting interactions. Our study indicates that high-resolution KIR genotyping informs post-transplant outcomes with a seemingly higher protection of educated NK cells.
    Journal
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3) • KIR2DS4 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 4) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    9ms
    EXPRESS: Osteoblasts inhibit NK cell killing function via RANK/RANKL in multiple myeloma. (PubMed, J Investig Med)
    Bone marrow osteoblasts in patients with MM may inhibit NK cell function via RANK/RANKL. Furthermore, denosumab combined with lenalidomide or pomalidomide can improve bone marrow NK cell function in these patients.
    Journal
    |
    LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • TNFRSF11A (TNF Receptor Superfamily Member 11a) • TNFSF11 (TNF Superfamily Member 11)
    |
    lenalidomide • pomalidomide • Prolia (denosumab)
    1year
    Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer. (PubMed, Front Immunol)
    The six-lncRNA pyroptosis-immune signature effectively predicted BC prognosis and highlighted distinct immune cell infiltration patterns. This holds promise for evaluating immunotherapy responses and guiding therapeutic target identification in BC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • CD40LG (CD40 ligand) • KIR2DS4 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 4) • MAPT (Microtubule Associated Protein Tau) • TDO2 (Tryptophan 2,3-Dioxygenase) • USP2-AS1 (USP2 Antisense RNA 1)
    1year
    IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CP. (PubMed, EJHaem)
    NK cell licensing may contribute to the potential efficacy of IFN-α treatment in patients with CML. We defined high-risk molecular relapse patients and suggest that KIR3DL1/HLA-Bw status may help detect patients who could benefit from IFN-α for maintaining TFR.
    Journal
    |
    KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • IFNA1 (Interferon Alpha 1)
    over1year
    IOS-1002, a Stabilized HLA-B57 Open Format, Exerts Potent Anti-Tumor Activity. (PubMed, Cancers (Basel))
    Lastly, IOS-1002 demonstrates efficacy in an ex vivo patient-derived tumor sample tumoroid model. IOS-1002 is a first-in-class multi-target and multi-functional human-derived HLA molecule that activates anti-tumor immunity and is currently under clinical evaluation.
    Journal
    |
    B2M (Beta-2-microglobulin) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1)
    |
    IOS-1002
    over1year
    HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis. (PubMed, Front Immunol)
    Our observations for the first time suggest that the HLA-KIR axis might be involved in anti-NMDAR encephalitis. While the genetic risk conferred by the identified polymorphisms appears small, a role of this axis in the pathophysiology of this disease appears highly plausible and should be analyzed in future studies.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • HHLA2 (HERV-H LTR-Associating 2) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    over1year
    IFNγ mediates the resistance of tumor cells to distinct NK cell subsets. (PubMed, J Immunother Cancer)
    Our data reveal that in the context of NK cells, IFNγ induces the resistance of tumor cells by the upregulation of classical and non-classical MHC-I. Moreover, we reveal insights into NK cell subset reactivity and propose a therapeutic strategy involving combinational monalizumab/lirilumab/DX9 treatment to fully restore the antitumor response across NK cell subsets.
    Journal • Tumor cell
    |
    IFNG (Interferon, gamma) • B2M (Beta-2-microglobulin) • IL2 (Interleukin 2) • HLA-E (Major Histocompatibility Complex, Class I, E) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    lirilumab (BMS-986015) • monalizumab (IPH2201)
    over1year
    Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder. (PubMed, Br J Dermatol)
    Alterations of KIR3DL1 gene may be of pathogenetic relevance for acral CD8+ TLPD. Loss of KIR3DL1 protein expression may support the diagnosis of this indolent lymphoma entity, albeit not being a subtype-specific discriminative feature.
    Journal
    |
    CD8 (cluster of differentiation 8) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1)